WEDNESDAY, April 23, 2025 — The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.The approval is for patients 12 years and older who remain…
You may also like
About 4 in 5 kidney transplant candidates never reach...
Ambient AI is already in the exam room. Is agentic AI...
Dementia risk similar for poor quality hearing aids...
Understanding the psychological impact of weight...
People continue to search Google for obesity lifestyle...
Key takeaways from new guideline on central precocious...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.